Skip to main content
. 2018 Aug 16;16:141. doi: 10.1186/s12916-018-1117-4

Table 3.

Results table

Screening algorithm Scenario Outcomes
Speciality Screening coverage CP-CRE prevalence Number of “days at risk” Total isolation bed days Total isolation bed days of patients without CP-CRE Cost per risk day averted (£) Average incremental cost per additional averted risk day (£)
(A) Direct PCR ICU 100% 1.6% 90 (4.39) 1500 (19.25) 368 (94.96) 198.45 743.56
63% 1.6% 508 (14.83) 991 (17.98) 244 (72.30) 192.18 712.38
63% 20% 5080 (36.20) 7649 (50.40) 173 (58.47) 58.18 97.10
100% 20% 918 (14.39) 11,834 (49.99) 263 (85.91) 58.69 99.57
(B) Culture +PCR 100% 1.6% 335 (9.31) 910 (17.59) 3 (5.55) 63.05
63% 1.6% 642 (14.06) 600 (15.84) 4 (10.01) 61.38
63% 20% 6664 (42.32) 5955 (38.82) 17 (20.84) 48.09
100% 20% 3308 (24.68) 9282 (53.2) 29 (38.32) 48.44
(C) PHE 100% 1.6% 221 (3.74) 1024 (19.37) 28 (31.95) 83.18 288.63
63% 1.6% 655 (14.00) 623 (17.57) 13 (18.32) 78.69 819.56
63% 20% 5194 (31.49) 7465 (45.2) 17 (21.47) 48.05 47.90
100% 20% 2309 (11.15) 10,287 (51.71) 41 (38.09) 49.68 61.23

The outcomes are given as the mean (standard deviation) from 100 simulations. The cost per risk day averted is the mean total cost divided by the mean number of “days at risk”. Total isolation bed days shown in bold text are greater than the existing total number of isolation bed days available to the ICU at ICHNT